Jain, Tania <br/><br/>
Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.  [electronic resource] 

 -  Leukemia  10 2019 
 - 2540-2544 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/s41375-019-0476-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>B-Lymphocytes--immunology<br/>Feasibility Studies<br/>Female<br/>Hematopoietic Stem Cell Transplantation--methods<br/>Humans<br/>Immunotherapy, Adoptive--adverse effects<br/>Lymphoma, B-Cell--immunology<br/>Lymphoma, Non-Hodgkin--immunology<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--immunology<br/>Receptors, Chimeric Antigen--immunology